Detailed information for compound 112110

Basic information

Technical information
  • TDR Targets ID: 112110
  • Name: 3-(dipropylamino)-3,4-dihydro-2H-chromen-6-ol
  • MW: 249.349 | Formula: C15H23NO2
  • H donors: 1 H acceptors: 1 LogP: 3.46 Rotable bonds: 5
    Rule of 5 violations (Lipinski): 1
  • SMILES: CCCN(C1COc2c(C1)cc(cc2)O)CCC
  • InChi: 1S/C15H23NO2/c1-3-7-16(8-4-2)13-9-12-10-14(17)5-6-15(12)18-11-13/h5-6,10,13,17H,3-4,7-9,11H2,1-2H3
  • InChiKey: COYBCQFIVNQGKW-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • 3-(dipropylamino)chroman-6-ol
  • 3-(dipropylamino)-3,4-dihydro-2H-1-benzopyran-6-ol
  • 6-hydroxy-3,4-dihydro-3-(dipropylamino)-2H-1-benzopyran
  • 3-(dipropylamino)-6-chromanol
  • 2H-1-Benzopyran-6-ol, 3-(dipropylamino)-3,4-dihydro-
  • 6-Hddpb
  • DP-6OH-3CA
  • Dipropyl-6-hydroxy-3-chromanamine

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Rattus norvegicus Dopamine D2 receptor Starlite/ChEMBL References
Rattus norvegicus Dopamine receptor Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus multilocularis serotonin receptor Dopamine D2 receptor   444 aa 428 aa 31.3 %
Onchocerca volvulus RB1-inducible coiled-coil protein 1 homolog Dopamine D2 receptor   444 aa 474 aa 23.4 %
Schistosoma mansoni amine GPCR Dopamine D2 receptor   444 aa 424 aa 32.1 %
Schistosoma japonicum Octopamine receptor, putative Dopamine D2 receptor   444 aa 456 aa 29.4 %
Schistosoma japonicum ko:K04135 adrenergic receptor, alpha 1a, putative Dopamine receptor   475 aa 398 aa 34.2 %
Schistosoma japonicum ko:K04207 neuropeptide Y receptor Y5, putative Dopamine D2 receptor   444 aa 386 aa 19.7 %
Onchocerca volvulus Glycoprotein hormone beta 5 homolog Dopamine D2 receptor   444 aa 476 aa 24.2 %
Onchocerca volvulus Dopamine D2 receptor   444 aa 418 aa 23.0 %
Echinococcus multilocularis g protein coupled receptor Dopamine D2 receptor   444 aa 465 aa 21.5 %
Schistosoma mansoni biogenic amine (dopamine) receptor Dopamine D2 receptor   444 aa 494 aa 26.3 %
Loa Loa (eye worm) hypothetical protein Dopamine D2 receptor   444 aa 433 aa 21.2 %
Schistosoma mansoni muscarinic acetylcholine (GAR) receptor Dopamine D2 receptor   444 aa 487 aa 23.8 %
Echinococcus granulosus g protein coupled receptor Dopamine D2 receptor   444 aa 457 aa 21.0 %
Schistosoma mansoni biogenic amine receptor Dopamine D2 receptor   444 aa 452 aa 30.1 %
Schistosoma japonicum ko:K04145 dopamine receptor D2, putative Dopamine D2 receptor   444 aa 432 aa 30.8 %
Echinococcus granulosus biogenic amine 5HT receptor Dopamine D2 receptor   444 aa 429 aa 31.7 %
Schistosoma japonicum ko:K04136 adrenergic receptor, alpha 1b, putative Dopamine D2 receptor   444 aa 440 aa 30.0 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Onchocerca volvulus 0.0437 1 1
Onchocerca volvulus 0.0437 1 1
Onchocerca volvulus 0.0437 1 1
Onchocerca volvulus 0.0437 1 1
Onchocerca volvulus 0.0437 1 1
Onchocerca volvulus 0.0437 1 1
Brugia malayi LBP / BPI / CETP family, C-terminal domain containing protein 0.0437 1 1
Loa Loa (eye worm) hypothetical protein 0.0437 1 1
Brugia malayi LBP / BPI / CETP family, N-terminal domain containing protein 0.0437 1 1
Loa Loa (eye worm) LBP/BPI/CETP family domain-containing protein 0.0437 1 1
Onchocerca volvulus 0.0437 1 1
Onchocerca volvulus 0.0437 1 1

Activities

Activity type Activity value Assay description Source Reference
Decrease (functional) = 100 % Inhibition of dopamine neuronal firing activity in the rat substantia nigra DA neutrons (2.2 mg/kg administered intraperitoneally) ChEMBL. 1967318
ED50 (functional) = 0.04 mg kg-1 Inhibition of gamma-butyrolactone-stimulated DOPA synthesis in the corpus striatum of rats (dose administered subcutaneously) ChEMBL. 1967318
ED50 (functional) = 0.17 mg kg-1 Inhibition of locomotor activity (LMA) in mice generated from four doses of 5-12 animals per dose (dose administered subcutaneously) ChEMBL. 1967318
ED50 (functional) = 0.17 mg kg-1 Dose required for inhibition of locomotor activity in mice (sc) ChEMBL. 3346882
ED50 (functional) = 0.17 mg kg-1 Inhibition of locomotor activity (LMA) in mice generated from four doses of 5-12 animals per dose (dose administered subcutaneously) ChEMBL. 1967318
ED50 (functional) = 0.85 mg kg-1 Dose (ip) giving half-maximal reversal of the gamma-butyrolactone-induced increase in DOPA formation of rat striatum ChEMBL. 3346882
ED50 (functional) = 11.3 mg kg-1 Inhibition of locomotor activity (LMA) in mice by the compound administered intraperitoneally. ChEMBL. 1967318
ED50 (functional) = 11.3 mg kg-1 Inhibition of locomotor activity (LMA) in mice by the compound administered intraperitoneally. ChEMBL. 1967318
ED50 (functional) = 13.4 mg kg-1 Reversal of reserpine-induced depression in rat (dose administered subcutaneously) Values generated from three doses;5-10 rats were used per dose. ChEMBL. 1967318
ED50 (functional) = 13.44 mg kg-1 Dose required for reversal of reserpine-induced depression in mice (sc) ChEMBL. 3346882
IC50 (binding) = 13.3 nM Affinity of the compound for [3H]-N-propylnorapomorphine (NPA) Dopamine receptor D2 ChEMBL. 1967318
IC50 (binding) = 13.3 nM In vitro affinity to dopamine receptor using [3H]-NPAD as radioligand in rat striatal membranes ChEMBL. 3346882
IC50 (binding) = 13.3 nM Affinity of the compound for [3H]-N-propylnorapomorphine (NPA) Dopamine receptor D2 ChEMBL. 1967318
IC50 (binding) = 13.3 nM In vitro affinity to dopamine receptor using [3H]-NPAD as radioligand in rat striatal membranes ChEMBL. 3346882
IC50 (binding) = 180 nM Potency of the compound to displace the specific in vitro binding of [3H]-DP-5,6-ADTN to rat striatal membrane ChEMBL. 2903247
IC50 (binding) = 180 nM Potency of the compound to displace the specific in vitro binding of [3H]-DP-5,6-ADTN to rat striatal membrane ChEMBL. 2903247
IC50 (binding) = 800 nM Concentration of the compound inhibiting specific binding of [3H]-haloperidol to Dopamine receptor D2 from rat striatal brain. ChEMBL. 1967318
IC50 (binding) = 800 nM In vitro affinity to dopamine receptor using [3H]-HPD as radioligand in rat striatal membranes ChEMBL. 3346882
IC50 (binding) = 800 nM Concentration of the compound inhibiting specific binding of [3H]-haloperidol to Dopamine receptor D2 from rat striatal brain. ChEMBL. 1967318
IC50 (binding) = 800 nM In vitro affinity to dopamine receptor using [3H]-HPD as radioligand in rat striatal membranes ChEMBL. 3346882
IC50 (binding) = 1400 nM Potency of the compound to displace the specific in vitro binding of [3H]-N-0437 to calf striatal membrane ChEMBL. 2903247
Increase (functional) = 100 % Inhibition of gamma-butyrolactone-stimulated DOPA synthesis in the corpus striatum of rats (30 mg/kg administered intraperitoneally) ChEMBL. 1967318
logD (ADMET) = 2.39 Partition coefficient of the compound in oct-buffer at a pH 7.4 ChEMBL. 2903247
pKa1 = 8.1 Ionization constant of the compound was determined in prosence of nitrogen ChEMBL. 2903247
pKa2 = 9.6 Ionization constant of the compound was determined in presence of hydroxyl ChEMBL. 2903247
Ratio (functional) = 79 Ratio of ED50 values for the inhibition of locomotor activity to reversal of reserpine-induced depression ChEMBL. 3346882

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

3 literature references were collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.